CN113423696A - 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的结晶形式及其配制品 - Google Patents

4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的结晶形式及其配制品 Download PDF

Info

Publication number
CN113423696A
CN113423696A CN202080013984.0A CN202080013984A CN113423696A CN 113423696 A CN113423696 A CN 113423696A CN 202080013984 A CN202080013984 A CN 202080013984A CN 113423696 A CN113423696 A CN 113423696A
Authority
CN
China
Prior art keywords
compound
formulation
crystalline form
amount
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080013984.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·P·布洛克
C·马赫瓦里
Q·梅德利
茂树宗登
M·蒙特奇-帕尔默
G·莫兰迪
M·马兹
K·斯塔西
C·S·托勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Ireland Ltd
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN113423696A publication Critical patent/CN113423696A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080013984.0A 2019-02-15 2020-02-13 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的结晶形式及其配制品 Pending CN113423696A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806697P 2019-02-15 2019-02-15
US62/806,697 2019-02-15
PCT/IB2020/051212 WO2020165840A1 (en) 2019-02-15 2020-02-13 Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof

Publications (1)

Publication Number Publication Date
CN113423696A true CN113423696A (zh) 2021-09-21

Family

ID=69740425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080013984.0A Pending CN113423696A (zh) 2019-02-15 2020-02-13 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的结晶形式及其配制品

Country Status (5)

Country Link
US (1) US12600702B2 (https=)
EP (2) EP4431497A1 (https=)
JP (3) JP2022520410A (https=)
CN (1) CN113423696A (https=)
WO (1) WO2020165840A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116419918A (zh) * 2020-08-06 2023-07-11 诺华股份有限公司 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的结晶形式及其配制品

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210129677A (ko) * 2019-02-15 2021-10-28 노파르티스 아게 안구 표면 통증의 치료 방법
WO2022105792A1 (zh) * 2020-11-17 2022-05-27 苏州晶云药物科技股份有限公司 一种喹唑啉酮衍生物的新晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1956721A (zh) * 2004-06-08 2007-05-02 诺瓦提斯公司 用作辣椒素拮抗剂的喹唑啉酮衍生物
CN102281920A (zh) * 2009-01-13 2011-12-14 诺瓦提斯公司 用作辣椒素拮抗剂的喹唑啉酮衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
EP3470059B1 (en) * 2015-01-26 2020-04-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
WO2022029656A1 (en) * 2020-08-06 2022-02-10 Novartis Ag Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1956721A (zh) * 2004-06-08 2007-05-02 诺瓦提斯公司 用作辣椒素拮抗剂的喹唑啉酮衍生物
CN102281920A (zh) * 2009-01-13 2011-12-14 诺瓦提斯公司 用作辣椒素拮抗剂的喹唑啉酮衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOVARTIS PHARMACEUTICALS: "Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery", HTTPS://CLINICALTRIALS.GOV/STUDY/NCT02961062COND=NCT02961062&RANK=1&TAB=HISTORY&A=7, 11 June 2018 (2018-06-11), pages 1 - 9 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116419918A (zh) * 2020-08-06 2023-07-11 诺华股份有限公司 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的结晶形式及其配制品

Also Published As

Publication number Publication date
JP2026004320A (ja) 2026-01-14
EP3924345A1 (en) 2021-12-22
US12600702B2 (en) 2026-04-14
JP2024161426A (ja) 2024-11-19
WO2020165840A1 (en) 2020-08-20
EP4431497A1 (en) 2024-09-18
US20220162170A1 (en) 2022-05-26
JP2022520410A (ja) 2022-03-30

Similar Documents

Publication Publication Date Title
AU2023203933B2 (en) Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
JP2024161426A (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤
CN113453686B (zh) 治疗眼表痛的方法
JP2026004313A (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤
RU2853589C2 (ru) Составы на основе 4-(7-гидрокси-2-изопропил-4-оксо-4h-хиназолин-3-ил)-бензонитрила
KR20260057219A (ko) 4-(7-히드록시-2-이소프로필-4-옥소-4h-퀴나졸린-3-일)-벤조니트릴의제형

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231122

Address after: Irish Dublin

Applicant after: Bausch & Lomb Ireland Ltd.

Address before: Basel, SUI

Applicant before: NOVARTIS AG

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210921